Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155358182> ?p ?o ?g. }
- W2155358182 endingPage "1784" @default.
- W2155358182 startingPage "1776" @default.
- W2155358182 abstract "Abstract This phase I safety study aimed to identify the optimal dose of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for combination studies. Using a crossover design, 15 patients with refractory tumors were allocated randomly to receive six sequential doses of DMXAA (300, 600, 1,200, 1,800, 2,400, and 3,000 mg m−2), each given once-weekly as a 20-minute i.v. infusion. The drug was generally well tolerated. Transient, moderate increases in the heart rate–corrected cardiac QT interval occurred at the two highest doses. DMXAA produced transient dose-dependent increases in blood pressure. Transient, dose-related visual disturbances occurred at the two highest doses. No significant changes in Ktrans and kep were observed but Ve, a secondary dynamic contrast–enhanced magnetic resonance imaging variable, increased significantly after giving DMXAA. At 1,200 mg m−2, the Cmax and the area under the concentration-time curve over 24 hours for total and free DMXAA plasma concentrations were 315 ± 25.8 μg/mL, 29 ± 6.4 μg/mL·d, 8.0 ± 1.77 μg/mL, and 0.43 ± 0.07 μg/mL·d, respectively. Plasma levels of the vascular damage biomarker 5-hydroxyindoleacetic acid increased in the 4 hours after treatment in a dose-dependent fashion up to 1,200 mg m−2, with a plateau thereafter. Doses in the range of 1,200 mg m−2 have been selected for further studies (phase II combination studies with taxanes and platins are under way) because this dose produced no significant effect on heart rate–corrected cardiac QT interval, produced near maximum levels of 5-hydroxyindoleacetic acid, achieved DMXAA plasma concentrations within the preclinical therapeutic range, and was well tolerated." @default.
- W2155358182 created "2016-06-24" @default.
- W2155358182 creator A5000993397 @default.
- W2155358182 creator A5003108180 @default.
- W2155358182 creator A5023626843 @default.
- W2155358182 creator A5038498358 @default.
- W2155358182 creator A5056423529 @default.
- W2155358182 creator A5061684371 @default.
- W2155358182 creator A5076996294 @default.
- W2155358182 date "2006-03-15" @default.
- W2155358182 modified "2023-09-26" @default.
- W2155358182 title "5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent" @default.
- W2155358182 cites W1965008165 @default.
- W2155358182 cites W1971801044 @default.
- W2155358182 cites W1975439149 @default.
- W2155358182 cites W1975725712 @default.
- W2155358182 cites W1976181892 @default.
- W2155358182 cites W1987471918 @default.
- W2155358182 cites W1989217478 @default.
- W2155358182 cites W1997995944 @default.
- W2155358182 cites W2002288054 @default.
- W2155358182 cites W2007551831 @default.
- W2155358182 cites W2009236534 @default.
- W2155358182 cites W2015386177 @default.
- W2155358182 cites W2016396157 @default.
- W2155358182 cites W2032841298 @default.
- W2155358182 cites W2035442859 @default.
- W2155358182 cites W2038145387 @default.
- W2155358182 cites W2047907992 @default.
- W2155358182 cites W2048325240 @default.
- W2155358182 cites W2051885336 @default.
- W2155358182 cites W2056304545 @default.
- W2155358182 cites W2056394928 @default.
- W2155358182 cites W2056944384 @default.
- W2155358182 cites W2057123987 @default.
- W2155358182 cites W2059020146 @default.
- W2155358182 cites W2061350341 @default.
- W2155358182 cites W2070757052 @default.
- W2155358182 cites W2091816154 @default.
- W2155358182 cites W2100255475 @default.
- W2155358182 cites W2111122418 @default.
- W2155358182 cites W2128078652 @default.
- W2155358182 cites W2138539226 @default.
- W2155358182 cites W2138613293 @default.
- W2155358182 cites W2150374672 @default.
- W2155358182 cites W2151608875 @default.
- W2155358182 doi "https://doi.org/10.1158/1078-0432.ccr-05-1939" @default.
- W2155358182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16551862" @default.
- W2155358182 hasPublicationYear "2006" @default.
- W2155358182 type Work @default.
- W2155358182 sameAs 2155358182 @default.
- W2155358182 citedByCount "87" @default.
- W2155358182 countsByYear W21553581822012 @default.
- W2155358182 countsByYear W21553581822013 @default.
- W2155358182 countsByYear W21553581822014 @default.
- W2155358182 countsByYear W21553581822015 @default.
- W2155358182 countsByYear W21553581822016 @default.
- W2155358182 countsByYear W21553581822017 @default.
- W2155358182 countsByYear W21553581822018 @default.
- W2155358182 countsByYear W21553581822019 @default.
- W2155358182 countsByYear W21553581822021 @default.
- W2155358182 countsByYear W21553581822022 @default.
- W2155358182 crossrefType "journal-article" @default.
- W2155358182 hasAuthorship W2155358182A5000993397 @default.
- W2155358182 hasAuthorship W2155358182A5003108180 @default.
- W2155358182 hasAuthorship W2155358182A5023626843 @default.
- W2155358182 hasAuthorship W2155358182A5038498358 @default.
- W2155358182 hasAuthorship W2155358182A5056423529 @default.
- W2155358182 hasAuthorship W2155358182A5061684371 @default.
- W2155358182 hasAuthorship W2155358182A5076996294 @default.
- W2155358182 hasBestOaLocation W21553581821 @default.
- W2155358182 hasConcept C112705442 @default.
- W2155358182 hasConcept C126322002 @default.
- W2155358182 hasConcept C142424586 @default.
- W2155358182 hasConcept C142724271 @default.
- W2155358182 hasConcept C159985019 @default.
- W2155358182 hasConcept C192562407 @default.
- W2155358182 hasConcept C204787440 @default.
- W2155358182 hasConcept C22979827 @default.
- W2155358182 hasConcept C27081682 @default.
- W2155358182 hasConcept C2776190711 @default.
- W2155358182 hasConcept C2780035454 @default.
- W2155358182 hasConcept C71924100 @default.
- W2155358182 hasConcept C84393581 @default.
- W2155358182 hasConcept C87813604 @default.
- W2155358182 hasConcept C98274493 @default.
- W2155358182 hasConceptScore W2155358182C112705442 @default.
- W2155358182 hasConceptScore W2155358182C126322002 @default.
- W2155358182 hasConceptScore W2155358182C142424586 @default.
- W2155358182 hasConceptScore W2155358182C142724271 @default.
- W2155358182 hasConceptScore W2155358182C159985019 @default.
- W2155358182 hasConceptScore W2155358182C192562407 @default.
- W2155358182 hasConceptScore W2155358182C204787440 @default.
- W2155358182 hasConceptScore W2155358182C22979827 @default.
- W2155358182 hasConceptScore W2155358182C27081682 @default.
- W2155358182 hasConceptScore W2155358182C2776190711 @default.
- W2155358182 hasConceptScore W2155358182C2780035454 @default.
- W2155358182 hasConceptScore W2155358182C71924100 @default.